Convergent Appoints Scott Myers as Chairman of its Board of Directors
CAMBRIDGE, Mass., Sept. 6, 2023 /PRNewswire/ -- Convergent Therapeutics Inc., a clinical-stage biotechnology company, today announced the expansion of its leadership team with the appointments of Neil Bander, MD, as Chief Scientific Officer, Eric M. Sullivan as Chief Financial Officer, and Dimitris Voliotis, MD, as Senior Vice President of Clinical Development. These appointments follow the company's recent closing of a $90 million Series A financing round to develop radiopharmaceuticals to treat cancer.
Convergent Therapeutics, a biotechnology company developing radiopharmaceuticals for cancer, said Wednesday that it has raised $90 million in a Series A financing led by venture investors OrbiMed and RA Capital Management.
CAMBRIDGE, Mass., May 3, 2023 /PRNewswire/ -- Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment of cancer, today announced the completion of a $90 million Series A financing, led by OrbiMed and RA Capital Management with participation from Invus. The financing will support the development of a pipeline of novel radioantibodies, including its lead program with CONV01-?, for the treatment of advanced prostate cancer.
Convergent Therapeutics has circled up $90M to develop next-gen radiopharmaceuticals, with its lead clinical program targeting prostate cancer.